- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.08. | Eli Lilly shares positive results for Jaypirca in head-to-head CLL/SLL study | ||
| 06.08. | Patient activation - not just a strategy but a necessity | ||
| 05.08. | BMS and Bain Capital launch new company to develop immunology therapies | ||
| 05.08. | CHMP recommends BeOne Medicines' Tevimbra for new lung cancer indication | ||
| 05.08. | Solving the patient engagement value equation | ||
| 04.08. | Biogen's Qalsody granted MHRA approval to treat rare form of motor neurone disease | ||
| 04.08. | FDA grants fast track designation to Nektar's rezpegaldesleukin in alopecia areata | ||
| 04.08. | The power of representation, innovation and trust in rare disease clinical trials | ||
| 01.08. | Sanofi's Sarclisa approved by EC to treat newly diagnosed multiple myeloma | ||
| 01.08. | Eli Lilly's Alzheimer's disease drug donanemab recommended by CHMP | ||
| 01.08. | Patient engagement - a journey of health activation | ||
| 31.07. | Merck unveils $3bn cost-cutting plan to support pipeline and new product launches | ||
| 31.07. | Havas Lynx appoints Talin Apkarian as Havas Lynx Hudson managing director | ||
| 30.07. | Moderna's LP.8.1-adapted COVID-19 vaccine recommended by CHMP | ||
| 30.07. | Havas Lynx appoints Ayesha Walawalkar as chief strategy officer | ||
| 29.07. | AstraZeneca's Imfinzi granted FDA priority review to treat early-stage gastric cancer | ||
| 29.07. | Roche shares promising data from Alzheimer's disease development portfolio | ||
| 28.07. | AbbVie's Elahere granted MHRA approval to treat platinum-resistant ovarian cancer | ||
| 28.07. | J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma | ||
| 25.07. | Novartis and Matchpoint enter inflammatory disease partnership worth $1bn | ||
| 25.07. | GSK's Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma | ||
| 25.07. | Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies | ||
| 24.07. | Johnson & Johnson's Darzalex approved by EC as first treatment for high-risk SMM | ||
| 24.07. | LEO's Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema | ||
| 24.07. | Abivax shares positive late-stage results for obefazimod in ulcerative colitis |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .